Innate Pharma Stock Shares Outstanding
| IPHYF Stock | USD 1.28 0.00 0.00% |
Innate Pharma fundamentals help investors to digest information that contributes to Innate Pharma's financial success or failures. It also enables traders to predict the movement of Innate Pink Sheet. The fundamental analysis module provides a way to measure Innate Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Innate Pharma pink sheet.
Innate |
Innate Pharma Company Shares Outstanding Analysis
Innate Pharma's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Innate Pharma Shares Outstanding | 80.21 M |
Most of Innate Pharma's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Innate Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Innate Pharma has 80.21 M of shares currently outstending. This is 55.57% lower than that of the Healthcare sector and 24.93% lower than that of the Biotechnology industry. The shares outstanding for all United States stocks is 85.97% higher than that of the company.
Innate Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Innate Pharma's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Innate Pharma could also be used in its relative valuation, which is a method of valuing Innate Pharma by comparing valuation metrics of similar companies.Innate Pharma is currently under evaluation in shares outstanding category among its peers.
Innate Fundamentals
| Return On Equity | -0.17 | |||
| Return On Asset | -0.043 | |||
| Profit Margin | (0.40) % | |||
| Operating Margin | (0.33) % | |||
| Current Valuation | 91.32 M | |||
| Shares Outstanding | 80.21 M | |||
| Shares Owned By Insiders | 22.50 % | |||
| Shares Owned By Institutions | 10.56 % | |||
| Price To Earning | 40.00 X | |||
| Price To Book | 1.48 X | |||
| Price To Sales | 3.27 X | |||
| Revenue | 12.11 M | |||
| Gross Profit | (22.3 M) | |||
| EBITDA | (36.88 M) | |||
| Net Income | (52.81 M) | |||
| Cash And Equivalents | 123.35 M | |||
| Cash Per Share | 1.54 X | |||
| Total Debt | 13.5 M | |||
| Debt To Equity | 0.37 % | |||
| Current Ratio | 2.34 X | |||
| Book Value Per Share | 1.46 X | |||
| Cash Flow From Operations | (58.46 M) | |||
| Earnings Per Share | (0.69) X | |||
| Number Of Employees | 213 | |||
| Beta | 0.33 | |||
| Market Capitalization | 275.93 M | |||
| Total Asset | 267.5 M | |||
| Z Score | 12.0 | |||
| Net Asset | 267.5 M |
About Innate Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Innate Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Innate Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Innate Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Innate Pink Sheet
When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in Innate Pink Sheet please use our How to Invest in Innate Pharma guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.